Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Onxeo SA   /   Onxeo 2020

Aandeel VALERIO TX PSE:ALVIO.FR, FR0010095596

Laatste koers (eur) Verschil Volume
0,075   +0,001   (+1,21%) Dagrange 0,071 - 0,075 31.178  

Onxeo 2020

Volgen
84 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste | Omlaag ↓
  1. forum rang 9 rationeel 21 oktober 2020 21:40
    Onxeo Announces Enrollment of First Patient
    in Phase Ib/II Study Revocan


    Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer
    First results from Revocan are expected early 2021
    ?
    The press release in PDF

    Paris (France), October 21, 2020 – 7.00 pm CEST - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced a new milestone in the clinical development of AsiDNA™ with the treatment of the first patient in the Revocan1 phase 1b/2 study designed to evaluate the effect of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, on the acquired resistance to PARP inhibitor (PARPi) niraparib for second line maintenance treatment of relapsed ovarian cancer. First results from this study are expected in early 2021.

    Globally, primary and acquired drug resistance and the resulting ineffectiveness of drug treatments are responsible for up to 90% of cancer-related deaths2. Acquired resistance to targeted therapies such as PARPi is a major concern in oncology: most, if not all, patients will eventually develop such a resistance3. Moreover, a new challenge has recently emerged for clinicians treating ovarian cancer patients: cross-resistance between PARP inhibitors and platinum, when resistance to PARPi impairs the efficacy of the subsequent chemotherapy4, especially after relapse, which occurs in 70% of these patients5.

    “Beyond tolerability outcomes, the Revocan clinical trial aims to provide the proof-of-concept of AsiDNA™’s ability, when added to a PARP inhibitor, to reverse acquired resistance to this otherwise very effective treatment. Revocan has been designed based on successful in-vivo experiments which closely mirrored its clinical protocol. Provided that the clinical study delivers the same positive results, we expect AsiDNA™ to become the first drug to address the critical challenge of acquired drug resistance.” said Olivier de Beaumont, Chief Medical Officer of Onxeo. “This proof-of-concept study would also pave the way for further clinical trials of AsiDNA™ in combination with other targeted therapies, in major indications with high unmet needs. This unique effect of AsiDNA™ on tumor resistance to treatment would address a major concern to oncologists and provide patients with a novel therapeutic option to better control their disease."

    The study plans to enroll up to 26 platinum-sensitive patients who have been treated with niraparib as a second-line maintenance therapy for at least six months, and who experience an elevation in CA 125, a well-established biomarker of ovarian cancer resistance to treatment. CA 125 is routinely measured in standard clinical practice and its rise is correlated to an impending disease progression, later confirmed by scan according to RECIST6 criteria.

    Led by Patricia Pautier, medical oncologist at Gustave Roussy (Paris, France) and principal investigator, the trial aims to demonstrate that the addition of AsiDNA™ to PARPi niraparib, when CA 125 has started to rise, leads to a significant and durable reduction of this biomarker, corresponding in a delay in the occurrence of tumor resistance. This would in turn results in stopping or slowing disease progression, thereby delaying the next treatment line as well as potentially increasing its efficacy. Progression-free survival and overall survival will also be assessed as longer term efficacy outcomes.

    The first patient in Revocan was treated at Gustave Roussy, the study sponsor under a clinical research agreement concluded with Onxeo in early 2020. Two other institutions7 are expected to start recruiting shortly. Additional centers, part of Arcagy Gineco, the French reference network for gynaecological cancers, will also participate into the study.

    References
    1Revocan = REV (Reversion of resistance) – OC (in Ovarian Cancer) – A (with AsiDNA™) – N (and Niraparib)
    2Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist 2019;2:141-160.
    3Klotz, D.M., Wimberger, P. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies. Arch Gynecol Obstet (2020)
    4Leary A. and Frenel JS. Communications at ESMO 2020 – Session ID 261: Mini Oral - Gynaecological cancers 1; Presentations ID 813MO & 5012 – Friday 18 September 2020.
    5Ovarian Cancer Research Alliance (OCRA): ocrahope.org/patients/about-ovarian-c...
    6RECIST (Response Evaluation Criteria in Solid Tumours)
    7Western Cancer Institute (Institut de Cancérologie de l’Ouest – Nantes/St Herblain) & University Hospital Center of Lyon (Hospices Civils de Lyon – CHU Lyon Sud)
  3. forum rang 9 rationeel 10 december 2020 18:58
    Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020

    Paris (France), December 10, 2020 – 6.00 pm CET - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, announced the transfer of the listing of its shares from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility on December 15, 2020.

    The application for the admission of Onxeo's shares to the Euronext Growth market in Paris was approved by the Euronext Admissions Committee on December 9, 2020.

    As a reminder, Onxeo had announced on July 29, 2010 its intention to transfer the listing of its shares to the Euronext Growth Paris multilateral trading facility. The transfer to Euronext Growth Paris is intended to enable Onxeo to be listed on a market more appropriate to the size of the company, to reduce the costs associated with listing, while enabling it to continue to benefit from the attractions of the financial markets.

    Onxeo will continue to provide accurate, precise and truthful information, making public any inside information concerning the company, in accordance with the European Regulation on Market Abuse (MAR Regulation).


    About Onxeo

    Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

    platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

    AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

    OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

    www.onxeo.com
  5. forum rang 9 rationeel 11 januari 2021 11:01
    Onxeo to Attend Key Investor and Scientific Conferences


    The press release in PDF

    Paris (France), January 11, 2021 – 7.00 am CET - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that its management team will attend the following key investor and scientific conferences in the coming months:

    H.C. Wainwright BioConnect 2021 Conference
    January 11-14, 2021 (virtual conference)
    For more information and to register, click here

    Biomed Event
    January 26-27, 2021 (virtual conference)
    For more information and to register, click here

    4TH Annual PARP & DDR Inhibitors Summit
    January 26-28, 2021 (virtual conference)
    For more information, click here

    Edison Open House Global Healthcare 2021
    January 26-28 2021 (virtual conference)
    For more information and to register, click here

    AACR Annual Meeting 2021
    April 9-14, 2021 (virtual conference)
    For more information and to register, click here


    * Given the evolving epidemic context, the reader is invited to refer to the organizers’ websites for possible updates to the conditions of participation.


    About Onxeo
    Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

    platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

    AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

    OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

    www.onxeo.com
  6. 25GTi 2 februari 2021 17:32
    @ rationeel
    Mooi dat je het nieuws bijhoudt van dit aandeel.

    In 2017 heb ik leuk aan dit aandeel verdiend. Naderhand heb ik steeds een kleine portie op de plank laten liggen voor het geval ze weer in de picture komen.
    Hun producten zijn nog in vroege ontwikkeling maar wie weet wat het ooit gaat opleveren....
  7. forum rang 9 rationeel 2 februari 2021 22:44
    “Despite the pandemic context, Onxeo has made significant progress in 2020 on several levels and expects a year 2021 rich in clinical catalysts.
    From a clinical perspective, we have initiated the phase 1b/2 study, REVOCAN, which aims to evaluate our lead candidate AsiDNA™ in combination with PARPi niraparib in relapsed ovarian cancer. This study, which will include up to 26 patients, is being conducted under the clinical research agreement with Gustave Roussy, the study sponsor, and began in the fourth quarter of 2020. Interim results will be provided in the course of the year, as they are made available by Gustave Roussy.
    As for the DRIIV-1b study combining AsiDNA™ to the chemotherapy, favorable interim results were published last November and we expect the study to be quickly completed. The efficacy signals observed allow us to work already on a phase 2 study of AsiDNA™ in the same combination in a specific indication with high unmet needs. We expect to submit this study to the regulatory authorities in the coming months, for an effective start this year.
    Finally, our second candidate, OX401 will continue its regulatory preclinical validation this year, and we are aiming to enter the clinical phase in 2022.
    The Company has also significantly improved its financial structure over the last 12 months, with several major transactions, including the recent approval of a €5 million state guaranteed loan which extends our financial visibility to the third quarter of 2022 and gives us the serenity we need to face 2021 and the uncertainties related in particular to the pandemic. Today, Onxeo has an ambitious and extensive R&D and clinical program, as well as the support of specialized investors such as Invus, and thus has the assets needed to achieve our goals," said Judith Greciet, Chief Executive Officer of Onxeo.

    To find out more about Onxeo's developments and prospects, we invite you to read Onxeo's Letter to Shareholders on our website.
  8. forum rang 9 rationeel 2 februari 2021 22:45
    quote:

    25GTi schreef op 2 februari 2021 17:32:

    @ rationeel
    Mooi dat je het nieuws bijhoudt van dit aandeel.

    In 2017 heb ik leuk aan dit aandeel verdiend. Naderhand heb ik steeds een kleine portie op de plank laten liggen voor het geval ze weer in de picture komen.
    Hun producten zijn nog in vroege ontwikkeling maar wie weet wat het ooit gaat opleveren....
    We hopen maar dat ons geduld eens beloond wordt:)
  9. forum rang 9 rationeel 4 februari 2021 21:37
    Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children

    About Institut Curie
    Institut Curie, French leading center for the fight against cancer, combines an internationally renowned research center and a state-of-the-art hospital group that treat all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie brings together more than... 3,600 ...researchers, doctors and healthcare professionals around its three missions: care, research and teaching.
    As a private foundation recognized for public utility and authorized to receive donations and bequests, Institut Curie can, thanks to the support of its donors, accelerate the discoveries and thus improve the treatment and the quality of life of the patients.
    For more information, visit institut-curie.org

    Paris (France), February 4, 2021 – 5:45 pm CET – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces that the Company has entered into a clinical research agreement with Institut Curie, the French leading cancer center, to conduct a phase 1b/2 study designed to evaluate the effect of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, in combination with radiotherapy in children with High-Grade Glioma (HGG) relapse and eligible to re-irradiation.

    High Grade Gliomas, representing about 20% of all pediatric central nervous system (CNS) tumors, still have a dismal outcome with a 5-year survival of less than 20%. Their standard treatment consists of surgical excision, in those locations where it is feasible, followed by radiotherapy (RT). In the absence of feasibility of surgical removal, a surgical biopsy is carried out to enable diagnosis. Radiotherapy is then performed alone or in association with chemotherapy and/or other medical treatments.

    “This collaboration represents another clinical milestone for Onxeo and reflects the Company's commitment to evaluate its drug candidate in indications with very high medical need, which is the case for this indication with a poor prognosis. The aim is to evaluate the synergy of the combination of AsiDNA™ with radiotherapy in order to improve treatment outcomes for these children suffering from relapsing High-Grade Glioma,” said Olivier de Beaumont, Chief Medical Officer of Onxeo. “We are excited and honored to be collaborating with the teams at Institut Curie, a world-renowned academic institution that we would like to thank, as well as the teams of Fight Kids Cancer for their support in this research aimed at improving the care of these children.”

    "We look forward to start this original proof-of-concept study of the systemic administration of AsiDNA™ in combination with radiotherapy in this disease with a poor prognosis: the development of new treatments meets a major need. This first study is supported by a grant from the European Fight Kids Cancer program, which we thank for their support, and is being conducted within the framework of the European ITCC[2] consortium. High-grade gliomas in children are a particularly severe disease and the treatments available are limited in terms of their efficacy but also in terms of their potential toxicity on the brain. Combined with radiotherapy, AsiDNA™ could represent a real therapeutic breakthrough, bringing together greater efficacy with a very reassuring tolerance profile”, said François Doz, MD, PhD, pediatrician oncologist, deputy director of clinical research, innovation and teaching at the SIREDO (Care, Innovation, Research, in oncology of children, adolescents and young adults) of Institut Curie and principal investigator of the study.

    He concludes: "We are delighted with this clinical development in pediatric oncology of AsiDNA™, an innovative therapy resulting from the work of Marie Dutreix's research laboratory at Institut Curie. If this study is positive, it could pave the way for further studies in association with radiotherapy, in children with brain tumors".

    Surgery, when possible, and radiotherapy, sometimes combined with chemotherapy, often allow control of the disease in high-grade gliomas in children, but this control is inconsistent and most usually transient because the tumors evolve secondarily due to the development of resistant tumor cells. In preclinical and clinical studies[3], the synergistic effect of AsiDNA™ in combination with "DNA breakers" such as radiotherapy has been demonstrated. Institut Curie and Onxeo collaborated on this multi-center phase 1b/2 trial design. Institut Curie, as study sponsor, will submit the application for authorization of this trial to the health authorities and ethics committees in the coming weeks, with the aim of initiating the study as early as 2021.

    [1] Fight Kids Cancer is a European call for projects, a joint initiative of the French association Imagine for Margo, the Belgian KickCancer Foundation and the Luxembourg Kriibskrank Kanner Foundation.
    [2] Innovative Therapies for Children with Cancer (ITCC) Consortium : www.itcc-consortium.org
    [3] First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. Le Tourneau C et al. Br J Cancer. 2016 May 24;114(11):1199-205
  10. forum rang 9 rationeel 4 februari 2021 21:40
    platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

    AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

    OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.
  13. forum rang 9 rationeel 10 maart 2021 20:06
    Onxeo Launches a Rights Issue
    to accelerate its R&D programs

    This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at least Q4 2022
    Target amount of €9.3 million, which may be increased to €10.7 million by exercise of the extension clause
    Rights issue open to the public in France and in Denmark
    Rights detached on March 17, 2021
    Subscription period: from March 19 to March 31, 2021 inclusive in France and from March 19 to March 26, 2021 inclusive in Denmark
    Subscription parity: 1 new share for 6 existing shares
    Subscription price: €0.71 (corresponding to DKK 5.29) per share, i.e. a 5.3% discount on the share price of March 8, 2021
    Transaction secured up to €7.0 million (75.5%) by subscription commitments from core shareholders Financière de la Montagne and Invus Public Equities LP.
  17. forum rang 9 rationeel 9 april 2021 13:01
    Onxeo to Present New Preclinical Data at AACR 2021
    Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors
    Introducing OX400, a new generation of PARP interfering cancer drug
    candidates
    Paris (France), April 8, 2021 – 6:00 pm CEST - Onxeo S.A. (Euronext Growth Paris: ALONX, First North
    Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the
    development of innovative drugs targeting tumor DNA Damage response (DDR), today announced the
    presentation of preclinical data confirming the differentiated antitumoral properties of the drug candidates
    generated by platON™, its patent-protected platform of decoy-agonists of the DNA Damage Response, in eposter sessions during the American Association for Cancer Research (AACR 2021) virtual annual meeting on April
    10, 2021.
    The first e-poster supports the ability of AsiDNA™, the Company’s first-in-class DNA Damage Response (DDR)
    inhibitor, to prevent resistance to KRAS inhibitors (KRASi) emerging from drug-tolerant persister cells (DTC).
    Novel therapies targeting the inhibition of KRAS, an oncogenic protein present in a third of cancers, have shown
    very promising clinical results especially in non-small cell lung cancer. However, acquired resistance hinders their
    efficacy. Combining AsiDNA™ to KRASi could be an additional development opportunity for AsiDNA™, in the
    context of its use to prevent acquired resistance to targeted therapies.
    The second e-poster describes the mechanism of action of the molecules of the new OX400 family, specifically
    designed to interfere with PARP signaling and display immunomodulatory properties and metabolic effects.
    Judith Greciet, Chief Executive Officer of Onxeo, commented: “Pharmaco-tolerant cells are a well-established
    cause of resistance to TKIs, and, as we already demonstrated last year, to PARP inhibitors. We have generated
    new data demonstrating that these cells are also involved in resistance to KRAS inhibitors and confirmed the
    efficacy of AsiDNA™ on these cells thus preventing or even reversing tumor regrowth. These results open the door
    for another potential combination with these innovative compounds which show high efficiency but struggle with
    resistance issues. In parallel, we continue to optimize the efficacy profile of the next candidates from the OX400
    family, while keeping the established benefits shared by all our platON™-sourced compounds in terms of safety
    and absence of resistance. Our new results confirm that, by trapping and exhausting specifically PARP, OX400
    compounds have the potential to modulate the immune response and wear out the tumor cell metabolism. We
    will continue to explore these original properties.”
  18. forum rang 9 rationeel 9 april 2021 13:07
    Session: PO.ET03.05 - Reversal of Drug Resistance E-poster: 1433
    Date/ Time: April 10, 2021 – 8:30 AM - 11:59 PM (U.S. Eastern Daylight Time -EDT)
    To read the abstract: Acquired resistance to KRASG12C inhibitors evolves from drug-tolerant persister cells
    vulnerable to AsiDNA™.
    Recent progress has been made in the development of therapeutics against KRASG12C mutated tumors, which represent
    approximately 15% of lung adenocarcinoma. However, therapeutic resistance to KRASG12C inhibition is still a clinical hurdle.
    As we have previously shown with PARP inhibitors, we describe in these new data that resistance to KRASG12C inhibitors could
    also emerge, at least in part, from drug-tolerant persister cells, a specific cell population that undergo “dormancy” during
    treatment and accumulate mutations enabling the development of resistance to KRASG12C inhibitors. AsiDNA™ can target
    specifically this source of resistance and therefore prevents the emergence of acquired resistance to KRASG12C inhibitors,
    pointing to the therapeutic opportunity of combining AsiDNA and KRASG12C to overcome tumor progression or relapse.
    Session: PO.CL06.07 - Immunomodulatory Agents and Interventions E-poster: 527
    Date/ Time: April 10, 2021 - 8:30 AM – 11:59 PM (U.S. Eastern Daylight Time -EDT)
    To read the abstract: A new generation of PARP interfering drug candidates for cancer treatment.
    Onxeo pioneered a new approach of anti-cancer treatment to tackle acquired drug resistance: the decoy agonist mechanism
    of action. Drugs based on this mechanism hijack and hyperactivate therapeutic targets leading to an impairment of their physiological function. Our first compound using this breakthrough decoy agonist action, AsiDNA™, has already shown target
    engagement, excellent safety profile in humans and importantly, lack of acquired resistance. We now describe the
    mechanism of action of our OX400 molecules, designed to trap PARP proteins. We show that these molecules, by interfering
    with PARP signaling, display immunomodulatory properties and metabolic effects. Our results provide a preclinical rationale
    for using OX400 molecules as immunomodulatory and “metabolic exhauster” agents, especially in appropriately molecularly
    selected patients with tumors showing metabolic deficiencies.
  20. forum rang 9 rationeel 9 december 2021 17:47
    Onxeo bondit de plus de 9% jeudi à la Bourse de Paris après la présentation de données précliniques confirmant les propriétés antitumorales de son composé AsiDNA.

    Ces résultats montrent que l'association d'AsiDNA et de thérapies ciblées empêche la réactivation des cellules DTP, une source majeure de résistance, évitant ainsi l'émergence de la résistance tumorale.

    Judith Greciet, la directrice générale de la société de biotechnologie, évoque des résultats 'particulièrement intéressants' ouvrant la voie à plusieurs stratégies d'association pour lutter contre la résistance tumorale.

    Pour mémoire, AsiDNA fait actuellement l'objet d'études cliniques en combinaison dans des tumeurs solides difficiles à traiter.

    Ces données ont été présentées lors de la conférence virtuelle EACR-AstraZeneca au cours de deux sessions dédiées.

    Copyright 2021 CercleFinance.com. Tous droits réservés.

    +15% vandaag:)
84 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee